re: mabs -
mabs are antibodies. One of the important differentiators is the region of the ab that sticks to it's target, called the 'variable' region. Think of typical antibodies as having two feet that stick. Peregrine is the only company working with therapeutic abs that deliberately target phospholpids. PS and other phospholipids have traditionally been considered "off limits" targets, but recently the folks at MD Anderson, (Alan Schroit etc.), have made discoveries into important differences into what look to be safe abs to phospholipids, (and why). If Peregrine's anti-PS works, ( actually I suppose I should say 'if it keeps working'), PS will be a very important target, as PS is the reason that so many diseases and critters get the better of us. (That wasn't really known at the time Thorpe was designing his anti-PS. His work came about for a different reason - because of his discovery of PS becoming exposed on tumor vasculature, but the understanding that PS itself is immunosuppressive - that it alters our immune response in a very fundamental way, was/is new, and it carries implications for treating "disease" itself, in the broadest sense imaginable). Our immune system recognizes PS as a universal symptom of dying host cells, and reacts accordingly - by clearing it up, but with a 'kinder/gentler' pro-growth response, and diseases like cancer, viruses, malaria, tuberculosis, etc, etc,..., seem to exploit this aspect of our immune response.
---------
j
News 
Market Data 
Discover 
AI
